Barcelona Science Park celebrates 20 years as a scientific and business innovation centre Blog Post

Yesterday, Barcelona Science Park (Parc Científic de Barcelona, PCB) held the first of a number of events scheduled to commemorate its 20 years as a meeting place for universities, companies and society. Established by the University of Barcelona (UB) in 1997 with the mission of promoting formulas to enhance research excellence, knowledge transfer and entrepreneurship, it was the first science park in Spain. Twenty years after the first brick was laid, the Barcelona Science Park is now one of Europe’s leading science, technology and business innovation parks for life sciences. Covering an area of over 100,000 m2, it boasts a wide range of scientific and technological infrastructures and an innovative community made up of more than 100 public and private entities and 2,700 professionals

 

UTOX-PCB takes part in the Preclinonco project to develop innovative new cancer drugs Blog Post

The Unit of Experimental Toxicology and Ecotoxicology of the Barcelona Science Park (PCB) is taking part in a consortium that aims to develop and provide preclinical checks for new candidates for first-in-class cancer drugs. The project, called Preclinonco, has just received an injection of nearly 350,000 euros from the Retos-Colaboración 2017 program, promoted by the Ministry of Science, Innovation and Universities with ERDF funding.

 

The Barcelona Science Park announces a new artistic intervention competition Blog Post

The Barcelona Science Park (PCB) is holding a new artistic intervention competition which offers participants the chance to design, with total freedom, a 125 metre-long space in the Cluster building, one of the main communication channels between the various research laboratories of the PCB. The ‘L’aigua és vida‘ [Water is life] project, by painter Kelly Arrontes, won the previous competition in 2017.

 

IBEC joins with Avinent to create prostheses that become real bone Blog Post

Advances in 3D bioprinted prostheses that are truly incorporated into the body –with their own blood vessels and sensitivity– are becoming increasingly more remarkable. This has been demonstrated by Avinent Implant System and the Biomaterials for Regenerative Therapies group led by Elisabeth Engell at the Institute for Bioengineering of Catalonia (IBEC), that are jointly developing an ambitious project to create 3D printed pieces from biomaterials.

 

Researchers design a nano-carrier to release drugs into damaged cells Blog Post

A team headed by the ICREA researcher Manuel Serrano at the Institute for Research in Biomedicine (IRB Barcelona), located in the Barcelona Science Park (PCB), has designed a drug encapsulation system that selectively targets senescent cells. The study, published in EMBO Molecular Medicine, paves the way for therapeutic approaches to eliminate these zombi cells in many diseases, such as pulmonary fibrosis and cancer. This is currently a central goal for many pharmaceutical companies, among them the one co-founded by Manuel Serrano himself Senolytic Therapeutics, based in PCB and in Boston.

 

New clues to analyse gene expression through epigenetics Blog Post

Researchers from the Centro Nacional de Análisis Genómico (CNAG-CRG), based in the Barcelona Science Park, and the Institut de Ciències del Mar (ICM-CSIC) have shown that the DNA region known as the first intron, a region to which not much attention had been paid until now, is a key region for analysing gene expression by epigenetic modifications. Anna Esteve-Codina, data analyst of the Functional Genomics team at the CNAG-CRG, is co-author of the paper.

 

SOM Biotech initiates of Phase 2a clinical trial of SOM3355 in Huntington’s disease patients Blog Post

SOM Biotech, a clinical-stage biopharmaceutical company –with headquarters in Barcelona Science Park– that discovers and develops drugs for orphan indications in the central nervous system,  has initiated of Phase 2a clinical trial of its compound SOM3355 for the treatment of the chorea movements associated to Huntington’s disease. The investigational product is a repositioned drug, currently commercialized for the treatment of hypertension. 

 

ilS, five years connecting companies with world experts in health sciences Blog Post

The consultancy firm Insights in Life Sciences (ilS), which is based at the Barcelona Science Park, is celebrating its fifth anniversary this year. With more than 100 projects under its belt, 40 clients and a network of 15,000 experts across the world, the company has consolidated itself as an exceptional liaison between pharma, biotech and medical device companies and life sciences’ Key Opinion Leaders (KOLs), with the aim of helping those Companies make suitable decisions for developing their products or successfully handling licence negotiation processes or funding rounds.